Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 5/2019

Open Access 01-10-2019 | Idiopathic Pulmonary Fibrosis | INTERSTITIAL LUNG DISEASE

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients

Authors: V. L. J. Proesmans, M. Drent, M. D. P. Elfferich, P. A. H. M. Wijnen, N. T. Jessurun, A. Bast

Published in: Lung | Issue 5/2019

Login to get access

Abstract

Purpose

Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive disease, which has a great impact on patients’ lives. Pirfenidone and nintedanib are approved and recommended antifibrotic drugs for patients with IPF. The aim of this study was to evaluate self-reported gastrointestinal side effects of antifibrotic drugs in 176 Dutch IPF patients.

Methods

A cross-sectional web-based anonymous survey about complaints and side effects was conducted among IPF patients in the Netherlands. Logistic regression was used to quantify whether pirfenidone and nintedanib caused complaints of nausea, vomiting, diarrhoea, appetite loss, weight loss or loss of taste or smell perception.

Results

The questionnaire was completed by 176 IPF patients, 71 of whom used pirfenidone and 85 nintedanib, while 20 patients did not use any antifibrotic drugs. Nintedanib users reported complaints of diarrhoea, vomiting, weight loss and loss of appetite (p < 0.01). Nausea was a significant adverse reaction (p < 0.05). Pirfenidone caused increased appetite loss (p < 0.01) and the risk of weight loss (p < 0.05). The increase in loss of appetite and weight loss did not differ significantly between the two drugs.

Conclusion

The current study showed that nintedanib causes a significant increase in diarrhoea, vomiting, weight loss and loss of appetite, while pirfenidone led to loss of appetite. Our results suggest new avenues regarding dietary recommendations for IPF patients.
Appendix
Available only for authorised users
Literature
1.
Ley B, Collard HR (2013) Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 5:483–492CrossRef
2.
Barratt SL, Creamer A, Hayton C, Chaudhuri N (2018) Idiopathic pulmonary fibrosis (IPF). An overview. J Clin Med 7(8):201CrossRef
3.
Raghu G, Rochwerg B, Zhang Y et al (2015) An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192(2):e3–e19CrossRef
4.
Zurkova M, Kriegova E, Kolek V et al (2019) Effect of pirfenidone on lung function decline and survival: 5-year experience from a real-life IPF cohort from the Czech EMPIRE registry. Respir Res 20(1):16CrossRef
5.
Yount SE, Beaumont JL, Chen S-Y, Kaiser K, Wortman K, Van Brunt DL, Swigris J, Cella D (2016) Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung 194(2):227–234CrossRef
6.
7.
Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44–e68CrossRef
8.
9.
Bennett D, Refini RM, Valentini ML, Fui A, Fossi A, Pieroni M, Mazzei MA, Rottoli P (2019) Pirfenidone therapy for familial pulmonary fibrosis: a real-life study. Lung 197(2):147–153CrossRef
10.
Crestani B, Huggins JT, Kaye M et al (2019) Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med 7(1):60–68CrossRef
11.
Fala L (2015) Ofev (Nintedanib): first tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis. Am Health Drug Benefits 8(Spec Feature):101PubMedPubMedCentral
12.
King TE Jr, Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. New Eng J Med 370(22):2083–2092CrossRef
13.
Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760–1769CrossRef
14.
15.
16.
Bonella F, Kreuter M, Hagmeyer L et al (2016) Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respir 92(2):98–106CrossRef
17.
Corte T, Bonella F, Crestani B et al (2015) Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 16(1):116CrossRef
18.
19.
Ogura T, Azuma A, Inoue Y et al (2015) All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig 53(5):232–241CrossRef
20.
Wijsenbeek MS, Grutters JC, Wuyts WA (2015) Early experience of pirfenidone in daily clinical practice in Belgium and the Netherlands: a retrospective cohort analysis. Adv Ther 32(7):691–704CrossRef
21.
Wardwell L, Chapman-Novakofski K, Brewer MS (2009) Effects of age, gender and chronic obstructive pulmonary disease on taste acuity. Int J Food Sci Nutr 60(sup6):84–97CrossRef
22.
Ito K, Kohzuki M, Takahashi T, Ebihara S (2014) Improvement in taste sensitivity following pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. J Rehab Med 46(9):932–936CrossRef
23.
Dewan NA, Bell CW, Moore J, Anderson B, Kirchain W, O’Donohue WJ Jr (1990) Smell and taste function in subjects with chronic obstructive pulmonary disease: effect of long-term oxygen via nasal cannulas. Chest 97(3):595–599CrossRef
24.
Williams L, Cohen M (1978) Altered taste thresholds in lung cancer. Am J Clin Nutri 31(1):122–125CrossRef
25.
Verhagen JV (2015) A role for lung retention in the sense of retronasal smell. Chemosens Percept 8(2):78–84CrossRef
26.
Ikeda H, Itasaka M, Takahashi K, Komatani A (1992) Prolonged lung retention of 123 I-IMP in pulmonary fibrosis. Ann Nucl Med 6(3):147CrossRef
27.
Valeyre D, Albera C, Bradford WZ et al (2014) Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 19(5):740–747CrossRef
28.
Costabel U, Richeldi L, du Bois RM et al (2015) Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: results of two 52-week, Phase III, randomized, placebo-controlled trials (INPULSIS™). Pneumologie 69(S 01):P235
29.
Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N (2016) Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med 5(9):78CrossRef
30.
Shaw J, Marshall T, Morris H, Hayton C, Chaudhuri N (2017) Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age. J Thorac Dis 9(11):4700–4707CrossRef
31.
Russell AM, Ripamonti E, Vancheri C (2016) Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’ perspectives of the disease and treatment. BMC Pulm Med 16:10CrossRef
32.
Duck A, Spencer LG, Bailey S, Leonard C, Ormes J, Caress AL (2015) Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis. J Adv Nurs 71(5):1055–1065CrossRef
33.
Costabel U, Bendstrup E, Cottin V et al (2014) Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 31(4):375–391CrossRef
34.
Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS (2009) Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 22(4):279–285CrossRef
35.
Mazzei ME, Richeldi L, Collard HR (2015) Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 9(3):121–129CrossRef
36.
Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356(9237):1255–1259CrossRef
37.
Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824CrossRef
38.
Metadata
Title
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
Authors
V. L. J. Proesmans
M. Drent
M. D. P. Elfferich
P. A. H. M. Wijnen
N. T. Jessurun
A. Bast
Publication date
01-10-2019
Publisher
Springer US
Published in
Lung / Issue 5/2019
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-019-00260-1

Other articles of this Issue 5/2019

Lung 5/2019 Go to the issue

COPD

A Polymorphism rs6726395 in Nrf2 Contributes to the Development of Emphysema-Associated Age in Smokers Without COPD

ACUTE LUNG INJURY

Prevention and Amelioration of Rodent Ventilation-Induced Lung Injury with Either Prophylactic or Therapeutic feG Administration

ELECTRONIC CIGARETTES

Electronic Cigarette Advertising Impacts Adversely on Smoking Behaviour Within a London Student Cohort: A Cross-Sectional Structured Survey

ASTHMA

Can EVH Results Predict Post-Exercise Changes in FEV1 Following Interval and Continuous Exercise?

COUGH

Impact of Cough and Unmet Needs in Chronic Cough: A Survey of Patients in Korea

SLEEP

The Frequency of Monocyte Chemoattractant Protein-1 Gene Polymorphism in Obstructive Sleep Apnea Syndrome

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits